Arcus Biosciences has a Cash Ratio of 4.33. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Arcus Biosciences's Cash Ratio or its related term are showing as below:
RCUS'
s Cash Ratio Range Over the Past 10 Years
Min: 3.01 Med: 5.99 Max: 17.83
Current: 4.33
During the past 9 years, Arcus Biosciences's highest Cash Ratio was 17.83. The lowest was 3.01. And the median was 5.99.
RCUS's Cash Ratio is ranked better than 63.13% of 1470
companies
in the Biotechnology industry
Industry Median: 2.71
vs RCUS: 4.33
Arcus Biosciences Cash Ratio Historical Data
The historical data trend for Arcus Biosciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Arcus Biosciences's Cash Ratio
For the Biotechnology subindustry, Arcus Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcus Biosciences's Cash Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcus Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Arcus Biosciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences (NYSE:RCUS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Arcus Biosciences Cash Ratio Related Terms
Thank you for viewing the detailed overview of Arcus Biosciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCUS has been successfully added to your 